tetano
Editor, Senior Moderator
Ann Hematol
. 2024 Jul 15.
doi: 10.1007/s00277-024-05869-8. Online ahead of print. Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia
Christina-Nefeli Kontandreopoulou[SUP] 1 [/SUP], Elena E Solomou[SUP] 2 [/SUP], Epaminondas Kolorizos[SUP] 1 [/SUP], Panagiotis T Diamantopoulos[SUP] 1 [/SUP]
Affiliations
Chronic lymphocytic leukemia (CLL) is characterized by disease- and treatment-related immunosuppression. Patients with CLL comprise a vulnerable population to coronavirus disease 2019 (COVID-19), while the protective effect of COVID-19 vaccination remains uncertain.We conducted a systematic review to evaluate published data reporting response to COVID-19 vaccination in patients with CLL. The primary outcome was the rate of seropositivity after full primary vaccination, while secondary outcomes were rates of positive neutralizing antibodies, cellular responses, and adverse events. Response after booster doses of vaccination was also evaluated.Twenty-three studies of full primary vaccination (12 CLL-specific with 1747 patients, 11 with mixed hematologic diseases including 1044 patients with CLL) with a total of 2791 patients, and eight studies on booster doses with 389 patients were included in the analysis. The serologic response varied between studies with a median of 55%. Where reported, the median neutralizing antibody response rate was 61.2% and the cellular response rate was 44.2%. Poor serologic response was noted in patients under active treatment with anti-CD20 monoclonal antibodies, BCL2, and BTK inhibitors.The present review highlights the substantially impaired humoral and cellular response to COVID-19 vaccination in patients with CLL with patients under active treatment being the most vulnerable.
Keywords: Cellular response; Chronic lymphocytic leukemia; Covid-19; Hematological malignancies; Humoral response; SARS-CoV-2; Seropositivity; Treatment; Vaccination.
. 2024 Jul 15.
doi: 10.1007/s00277-024-05869-8. Online ahead of print. Vaccine challenges in CLL: a comprehensive exploration of efficacy of SARS-CoV-2 immunization for patients with chronic lymphocytic leukemia
Christina-Nefeli Kontandreopoulou[SUP] 1 [/SUP], Elena E Solomou[SUP] 2 [/SUP], Epaminondas Kolorizos[SUP] 1 [/SUP], Panagiotis T Diamantopoulos[SUP] 1 [/SUP]
Affiliations
- PMID: 39008060
- DOI: 10.1007/s00277-024-05869-8
Chronic lymphocytic leukemia (CLL) is characterized by disease- and treatment-related immunosuppression. Patients with CLL comprise a vulnerable population to coronavirus disease 2019 (COVID-19), while the protective effect of COVID-19 vaccination remains uncertain.We conducted a systematic review to evaluate published data reporting response to COVID-19 vaccination in patients with CLL. The primary outcome was the rate of seropositivity after full primary vaccination, while secondary outcomes were rates of positive neutralizing antibodies, cellular responses, and adverse events. Response after booster doses of vaccination was also evaluated.Twenty-three studies of full primary vaccination (12 CLL-specific with 1747 patients, 11 with mixed hematologic diseases including 1044 patients with CLL) with a total of 2791 patients, and eight studies on booster doses with 389 patients were included in the analysis. The serologic response varied between studies with a median of 55%. Where reported, the median neutralizing antibody response rate was 61.2% and the cellular response rate was 44.2%. Poor serologic response was noted in patients under active treatment with anti-CD20 monoclonal antibodies, BCL2, and BTK inhibitors.The present review highlights the substantially impaired humoral and cellular response to COVID-19 vaccination in patients with CLL with patients under active treatment being the most vulnerable.
Keywords: Cellular response; Chronic lymphocytic leukemia; Covid-19; Hematological malignancies; Humoral response; SARS-CoV-2; Seropositivity; Treatment; Vaccination.